GenoFocus Inc (187420) - Total Liabilities
Based on the latest financial reports, GenoFocus Inc (187420) has total liabilities worth ₩82.66 Billion KRW (≈ $56.02 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GenoFocus Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how GenoFocus Inc's total liabilities have evolved over time, based on quarterly financial data. See 187420 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
GenoFocus Inc Competitors by Total Liabilities
The table below lists competitors of GenoFocus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Getty Copper Inc.
V:GTC
|
Canada | CA$602.88K |
|
Taiwan Enterprise(Cayman)Co
TW:5906
|
Taiwan | NT$1.26 Billion |
|
Lithium South Development Corp
V:LIS
|
Canada | CA$1.20 Million |
|
Soluciones Cuatroochenta S.L.
MC:480S
|
Spain | €36.30 Million |
|
Angkor Resources Corp
V:ANK
|
Canada | CA$5.86 Million |
|
COLUMBUS ENERGY S.A. ZY 7
F:0Q8
|
Germany | €217.79 Million |
|
Romerike Sparebank
OL:ROMER
|
Norway | Nkr16.57 Billion |
|
DSR Corp
KO:155660
|
Korea | ₩151.69 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down GenoFocus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is GenoFocus Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GenoFocus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GenoFocus Inc (2014–2025)
The table below shows the annual total liabilities of GenoFocus Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩81.08 Billion ≈ $54.95 Million |
-33.81% |
| 2024-12-31 | ₩122.49 Billion ≈ $83.01 Million |
+71.31% |
| 2023-12-31 | ₩71.50 Billion ≈ $48.46 Million |
-35.01% |
| 2022-12-31 | ₩110.02 Billion ≈ $74.56 Million |
+32.17% |
| 2021-12-31 | ₩83.24 Billion ≈ $56.41 Million |
+13.32% |
| 2020-12-31 | ₩73.46 Billion ≈ $49.78 Million |
+92.90% |
| 2019-12-31 | ₩38.08 Billion ≈ $25.81 Million |
+276.16% |
| 2018-12-31 | ₩10.12 Billion ≈ $6.86 Million |
+70.65% |
| 2017-12-31 | ₩5.93 Billion ≈ $4.02 Million |
+735.70% |
| 2016-12-31 | ₩709.87 Million ≈ $481.07K |
-3.57% |
| 2015-12-31 | ₩736.18 Million ≈ $498.90K |
-89.89% |
| 2014-12-31 | ₩7.28 Billion ≈ $4.93 Million |
-- |
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phy… Read more